Geneva: The UN health agency says the world's largest randomized trial of COVID-19 treatments found "conclusive evidence" that remdesivir, a drug used to treat U.S. President Donald Trump when he fell ill, has little or no effect on severe cases.
The World Health Organization announced Friday the long-awaited results of its six-month "Solidarity Therapeutics Trial" that endeavored to see if existing drugs might have an effect on the coronavirus.
Remdesivir, a repurposed malaria drug, has been classified as standard-of-care in the United States, and it has been approved for use against COVID-19 in the UK and EU. Supplies of the drug have been limited, and the European Medicines Agency is now reviewing whether remdesivir is causing kidney problems as reported by some patients.
Read also: WHO warns there might never be a 'silver bullet' to defeat virus
Martin Landray, a professor of medicine and epidemiology at Oxford University, said the WHO trial results for hydroxychloroquine and lopinavir were in line with a previous British study he co-led.
"The big story is the finding that remdesivir produces no meaningful impact on survival," he said in a statement. He said the drug is now recommended in some countries but there have been significant concerns about supply, cost and access.
"This is a drug that has to be given by intravenous infusion for 5 to 10 days," noting it costs about $2,550 per treatment course. "COVID affects millions of people and their families around the world. We need scalable, affordable, and equitable treatments."
A cocktail of treatments given to President Trump after he tested positive for the coronavirus included remdesivir.
WHO said the study, which covered more than 30 countries, looked at the effects of the treatments on overall death rates, whether or not patients need breathing machines, and how much time patients spent recovering in hospitals.
AP
